Tessa Romero
Stock Analyst at J.P. Morgan
(4.67)
# 825
Out of 4,564 analysts
192
Total ratings
57.1%
Success rate
20.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYPT EyePoint | Maintained: Buy | $33 → $30 | $12.47 | +140.58% | 7 | Jul 22, 2026 | |
| BHVN Biohaven | Maintained: Buy | n/a | $14.65 | - | 14 | Jun 30, 2026 | |
| LRMR Larimar Therapeutics | Reiterated: Buy | $9 | $4.01 | +124.44% | 2 | Jun 29, 2026 | |
| LXEO Lexeo Therapeutics | Maintained: Buy | $9 | $4.71 | +91.08% | 4 | Jun 25, 2026 | |
| UPB Upstream Bio | Downgraded: Hold | $8 | $6.40 | +25.00% | 10 | Jun 12, 2026 | |
| AGIO Agios Pharmaceuticals | Rated: Hold | $31 | $36.28 | -14.55% | 17 | Jun 11, 2026 | |
| NRIX Nurix Therapeutics | Maintained: Buy | n/a | $23.74 | - | 3 | Jun 11, 2026 | |
| SPTX Seaport Therapeutics | Reiterated: Buy | $42 | $21.94 | +91.43% | 2 | Jun 8, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | $97 | $81.92 | +18.41% | 32 | Jun 5, 2026 | |
| EWTX Edgewise Therapeutics | Rated: Buy | $45 → $53 | $39.29 | +34.89% | 21 | Jun 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 | $11.44 | +101.05% | 4 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $80 → $82 | $65.42 | +25.34% | 15 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $1.56 | - | 5 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $56 | $49.48 | +13.18% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $3.28 | - | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $38 | $33.47 | +13.53% | 3 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $17 → $16 | $23.89 | -33.03% | 13 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $34 | $24.83 | +36.93% | 19 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.97 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $5.23 | n/a | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.21 | n/a | 4 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 → $10 | $8.17 | n/a | 2 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $36.82 | n/a | 1 | Nov 9, 2020 |
EyePoint
Jul 22, 2026
Maintained: Buy
Price Target: $33 → $30
Current: $12.47
Upside: +140.58%
Biohaven
Jun 30, 2026
Maintained: Buy
Price Target: n/a
Current: $14.65
Upside: -
Larimar Therapeutics
Jun 29, 2026
Reiterated: Buy
Price Target: $9
Current: $4.01
Upside: +124.44%
Lexeo Therapeutics
Jun 25, 2026
Maintained: Buy
Price Target: $9
Current: $4.71
Upside: +91.08%
Upstream Bio
Jun 12, 2026
Downgraded: Hold
Price Target: $8
Current: $6.40
Upside: +25.00%
Agios Pharmaceuticals
Jun 11, 2026
Rated: Hold
Price Target: $31
Current: $36.28
Upside: -14.55%
Nurix Therapeutics
Jun 11, 2026
Maintained: Buy
Price Target: n/a
Current: $23.74
Upside: -
Seaport Therapeutics
Jun 8, 2026
Reiterated: Buy
Price Target: $42
Current: $21.94
Upside: +91.43%
Cytokinetics
Jun 5, 2026
Maintained: Buy
Price Target: $97
Current: $81.92
Upside: +18.41%
Edgewise Therapeutics
Jun 5, 2026
Rated: Buy
Price Target: $45 → $53
Current: $39.29
Upside: +34.89%
Jun 3, 2026
Maintained: Buy
Price Target: $23
Current: $11.44
Upside: +101.05%
May 27, 2026
Rated: Buy
Price Target: $80 → $82
Current: $65.42
Upside: +25.34%
May 26, 2026
Maintained: Sell
Price Target: n/a
Current: $1.56
Upside: -
May 8, 2026
Maintained: Buy
Price Target: $50 → $56
Current: $49.48
Upside: +13.18%
Apr 2, 2026
Maintained: Sell
Price Target: n/a
Current: $3.28
Upside: -
Mar 24, 2026
Rated: Buy
Price Target: $38
Current: $33.47
Upside: +13.53%
Mar 16, 2026
Maintained: Hold
Price Target: $17 → $16
Current: $23.89
Upside: -33.03%
Mar 4, 2026
Rated: Buy
Price Target: $31 → $34
Current: $24.83
Upside: +36.93%
Nov 18, 2025
Maintained: Hold
Price Target: n/a
Current: $2.97
Upside: -
Oct 23, 2024
Downgraded: Sell
Price Target: n/a
Current: $5.23
Upside: n/a
Oct 18, 2024
Maintained: Hold
Price Target: n/a
Current: $3.21
Upside: n/a
Jul 13, 2022
Downgraded: Hold
Price Target: $22 → $10
Current: $8.17
Upside: n/a
Nov 9, 2020
Downgraded: Hold
Price Target: n/a
Current: $36.82
Upside: n/a